Carregant...
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over time several randomized phase III trials have been performed testing sunitinib, brivanib, linifanib and other molecules...
Guardat en:
| Publicat a: | World J Hepatol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4539398/ https://ncbi.nlm.nih.gov/pubmed/26301047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i17.2053 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|